Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Scheduling of Pre-Dose Fasting Period – V 2.0

Posted on By

BA-BE Studies: SOP for Scheduling of Pre-Dose Fasting Period – V 2.0

Standard Operating Procedure for Scheduling of Pre-Dose Fasting Period in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/058/2025
Supersedes SOP/BA-BE/058/2022
Page No. Page 1 of 10
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To establish a standard procedure for scheduling and enforcing the pre-dose fasting period for study participants in Bioavailability/Bioequivalence (BA/BE) studies to ensure valid pharmacokinetic evaluations and adherence to protocol.

2. Scope

This SOP applies to all BA/BE clinical studies conducted at the facility where fasting prior to dosing is a protocol-mandated requirement. It covers subject instructions, meal restrictions, monitoring, and documentation procedures.

3. Responsibilities

  • Clinical Research Coordinator (CRC): Communicates fasting instructions, schedules last meal, and ensures volunteer compliance.
  • Ward In-charge/Nurse: Monitors and documents fasting start time and confirms adherence at dosing.
  • Principal Investigator (PI): Approves pre-dose readiness and confirms protocol compliance.
See also  BA-BE Studies: SOP for Review of Bioequivalence Waiver Justifications (BCS Class I) - V 2.0

4. Accountability

The Study PI is accountable for ensuring that all enrolled subjects have completed the required fasting period prior to dosing, as defined by the study protocol.

5. Procedure

5.1 Determination of Fasting Period

  1. Refer to the clinical protocol to confirm the exact fasting requirement (e.g., 10 hours overnight fasting).
  2. Document the protocol-specified fasting duration in Annexure-1: Fasting Period Reference Sheet.

5.2 Scheduling Last Meal

  1. Arrange a light standardized dinner for all volunteers as per protocol (generally low-fat, <30% calories from fat).
  2. Serve dinner at a scheduled time (e.g., 8:00 PM) and document meal composition in Annexure-2: Pre-Dose Meal Record.

5.3 Initiation of Fasting

  1. Confirm start time of fasting for each subject immediately after last meal intake (e.g., 8:30 PM).
  2. Restrict food, beverages (except water), chewing gum, and tobacco post fasting initiation.
  3. Water is permitted as per protocol (e.g., up to 1 hour prior to dosing).
See also  BA-BE Studies: SOP for Review of SmPC for EU BA/BE Submissions - V 2.0

5.4 Fasting Monitoring

  1. Assign nursing staff to monitor and document compliance in Annexure-3: Fasting Monitoring Log.
  2. Check with subjects for any fasting violations (e.g., consumption of food or restricted items).

5.5 Confirmation Prior to Dosing

  1. Before dosing, reconfirm fasting duration for each subject (must be equal to or more than protocol requirement).
  2. Investigators or Sub-Investigators to verify and sign Annexure-4: Fasting Compliance Declaration.

5.6 Non-Compliance Handling

  1. Document any deviation from fasting requirements.
  2. Inform PI for decision on subject inclusion or replacement.
  3. Record the incident in the protocol deviation log if required.

6. Abbreviations

  • BA: Bioavailability
  • BE: Bioequivalence
  • PI: Principal Investigator
  • CRC: Clinical Research Coordinator

7. Documents

  1. Fasting Period Reference Sheet – Annexure-1
  2. Pre-Dose Meal Record – Annexure-2
  3. Fasting Monitoring Log – Annexure-3
  4. Fasting Compliance Declaration – Annexure-4

8. References

  • ICH E6(R2) – Good Clinical Practice
  • CDSCO Guidelines for BA/BE Studies
  • Study Protocol
See also  BA-BE Studies: SOP for Pre-Study Kickoff Meeting Conduct - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Fasting Period Reference Sheet

Study Code Fasting Requirement Reference (Protocol Section)
BE2025-058 10 hours Section 5.1

Annexure-2: Pre-Dose Meal Record

Subject ID Meal Type Meal Time Supervised By
VOL-058 Standard Low-Fat 20:00 Sunita Reddy

Annexure-3: Fasting Monitoring Log

Subject ID Fasting Start Time Monitoring Interval Compliance Noted Initials
VOL-058 20:30 Every 2 hrs Yes R. Pawar

Annexure-4: Fasting Compliance Declaration

Subject ID Fasting Duration Fit for Dosing Verified By (Investigator) Date
VOL-058 10 hrs Yes Dr. Arvind Shah 17/04/2025

Revision History:

Revision Date Revision No. Details Reason Approved By
15/01/2022 1.0 Initial release Protocol implementation QA Head
17/04/2025 2.0 Detailed monitoring and annexures added Operational clarity QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: API Manufacturing: SOP for Work-Up Procedure After Reaction Completion – V 2.0
Next Post: SOP for Secure Storage and Access Control for High-Purity Solvents – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version